Table 4.
Multiple linear regression analysis of association of microangiopathy with duration of AED therapy and other candidate risk factors.
| Urine albumin/creatinine ratio |
Retinal vein diameter |
|||||
|---|---|---|---|---|---|---|
| Variables | B | SE | p Value | B | SE | p Value |
| Age | −0.119 | −1.366 | 0.175 | −0.117 | −1.373 | 0.173 |
| Body mass index | −0.074 | −0.791 | 0.431 | 0.069 | 0.818 | 0.415 |
| Duration of AED therapy | −0.020 | −0.227 | 0.821 | 0.515 | 3.340 | 0.001* |
| EIAEDs | −0.122 | −1.399 | 0.165 | 0.203 | 2.143 | 0.034* |
| Duration of EIAED therapy | 0.047 | 0.539 | 0.591 | −0.526 | −5.764 | <0.001* |
| Duration of non-EIAED therapy | −0.062 | −0.702 | 0.484 | 0.093 | 1.113 | 0.268 |
| AED number | 0.081 | 0.920 | 0.360 | 0.086 | 1.036 | 0.303 |
| hs-CRP | 0.199 | 2.297 | 0.023* | 0.075 | 0.933 | 0.353 |
| Total cholesterol | 0.137 | 1.521 | 0.133 | 0.007 | 0.092 | 0.927 |
| LDL-C | 0.086 | 0.964 | 0.337 | 0.003 | 0.036 | 0.972 |
| Triglyceride | 0.308 | 3.559 | 0.001* | 0.070 | 0.818 | 0.415 |
| Glycated hemoglobin (HbA1c) | 0.028 | 0.322 | 0.748 | 0.079 | 0.982 | 0.328 |
| Creatinine | −0.151 | −1.672 | 0.097 | 0.230 | 2.833 | 0.005* |
AED, antiepileptic drug, EIAEDs, enzyme-inducing antiepileptic drugs, hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index.
The duration of AED therapy was considered 0 in the control group.
*p < 0.0.5.